Close
Help


Safety of L. Reuteri in Infant Formula

Posted Wed, Apr, 23,2014

Published today in Nutrition and Metabolic Insights is a new original research article by Konstantinos Papagaroufalis, Aikaterini Fotiou, Delphine Egli, Liên-Anh Tran and Philippe Steenhout.  Read more about this paper below:

Title

A Randomized Double Blind Controlled Safety Trial Evaluating D-Lactic Acid Production in Healthy Infants Fed a Lactobacillus reuteri-containing Formula

Abstract

Background: D-Lactic acidosis in infants fed lactic acid bacteria-containing products is a concern.

Methods: The primary objective of this non-inferiority trial was to compare urinary D-lactic acid concentrations during the first 28 days of life in infants fed formula containing Lactobacillus reuteri (1.2 x 10⁶ colony forming units (CFU)/ml) with those fed a control formula. The non-inferiority margin was set at a two-fold increase in D-lactic acid (0.7 mmol/mol creatinine, log-transformed). Healthy term infants in Greece were enrolled between birth and 72 hours of age, and block randomized to a probiotic (N = 44) or control (N = 44) group. They were exclusively fed their formulae until 28 days of age and followed up at 7, 14, 28, 112, and 168 ± 3 days. Anthropometric measurements were taken at each visit and tolerance recorded until 112 days. Urine was collected before study formula intake and at all visits up to 112 days and blood at 14 days.

Results: D-Lactic acid concentration in the probiotic group was below the non-inferiority margin at 28 days: treatment effect -0.03 (95% confidence interval [CI]: [-0.48 to 0.41]) mmol/mol creatinine but was above the non-inferiority margin at 7 and 14 days—treatment effect 0.50 (95% CI: [0.05–0.96]) mmol/mol creatinine and 0.45 (95% CI: [0.00–0.90]) mmol/mol creatinine, respectively. Blood acid excess and pH, anthropometry, tolerance, and adverse events (AEs) were not significantly different between groups.

Conclusion: Intake of L. reuteri-containing formula was safe and did not cause an increase in D-lactic acid beyond two weeks.

Trial Registration: ClinicalTrials.gov NCT01119170.

Click here to learn more about the article, download it and comment

share on

Posted in: Articles Published

  • Efficient Processing: 4 Weeks Average to First Editorial Decision
  • Fair & Independent Expert Peer Review
  • High Visibility & Extensive Database Coverage
Services for Authors
What Your Colleagues Say About Libertas Academica
It is an absolute pleasure serving as a peer reviewer for Libertas Academia. The review process was efficient and easy to navigate.  I am looking forward to peer reviewing additional articles in the future.
Dr Samuel S. Grossman (New York Harbor Health Care System, New York, NY, USA)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube